# Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions

> **NCT00960310** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 36 (actual)

## Conditions studied

- Prostate Cancer
- Hirsutism

## Interventions

- **DRUG:** Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
- **DRUG:** Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)

## Key facts

- **NCT ID:** NCT00960310
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960310, "Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00960310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*